Fluoroquinolone類抗生素 Treatment of urinary tract infections, chronic bronchitis, community-acquired pneumonia (including penicillin-resistant Streptococcus pneumoniae), skin and skin structure infections, and maxillary sinusitis.

Levofloxavin is the active L-isomer of ofloxacin that allow higher dosages of the active form to be given with fewer side effects.

Bioavailability: 99%, Oral and intravenous routes of administration are considered interchangeable; Distribution: high concentrations are achieved in prostate, lung, and gynecological tissues, sinus, saliva; primarily excreted from urine as unchanged drug (87%); Elimination half-life: 6-8 hrs.

Hypersensitivity to levofloxacin, other fluoroquinolones

C

Excretion in breast milk unknown/not recommended

Nausea, headache, diarrhea, insomnia, dizziness, and constipation.

Adults:
IV for chronic bronchitis－500 mg QD for at least 7 days.
IV for pneumonia, sinusitis, and skin infections－750 mg QD for 5 days ( 7-14 days, if nosocomial pneumonia).
IV for UTI－250 mg QD for 3-10 days OR 750 mg QD for 5 days.
IV for prostatitis－500 mg QD for 28 days.
Safety and efficacy in children under 18 years of age have not been established (oral/IV).

After an initial dose of 750mg QD,
Clcr 20~49 ml/min: 750 mg Q48 H; Clcr up to 19 ml/min (including HD/CAPD): 500 mg Q48 H.
After an initial dose of 500mg QD,
Clcr 20~49 ml/min: 250mg QD; Clcr up to 19 ml/min (including HD/CAPD): 250mg Q48H.
After an initial dose of 250mg QD, Clcr 10~19 ml/min: 250mg Q48H

使用前才可從外盒取出，須避光於原包裝儲存，若外盒除去則有效期限為3天。原裝瓶橡皮塞被穿刺後，應於3小時內使用，以避免污染。